ASCO Updates Breast Cancer Follow-Up Guidelines With Risk-Based Surveillance Approach
RICE Study: Can Immune Checkpoint Inhibitors Be Used Again After Progression?
Vincent Rajkumar: Limited Duration of Lenalidomide Maintenance is Just as Good as Indefinite Therapy
The System Behind Access of New Cancer Drugs with Lisa Thompson Smith
Tucatinib Plus Trastuzumab Deruxtecan Shows Activity but No Clear Added Benefit in HER2+ Advanced Breast Cancer
Durvalumab With Radiation Shows Promise in Chemotherapy-Ineligible Locally Advanced NSCLC
Lovett Evan Reddick: Honored to Join GSK as Executive Director, Emerging Therapeutic Areas
The Thirteen-Minute Infusion: What Sarclisa's Wearable Injector Signals for Cancer Care
